life scienc tool diagnost
three-year medium-term guidanc call acceler revenu growth
across technolog ta incl bp research
rd incl bp pass bp increment
million cost save next three year also support
continu dd ep growth rais ep
ep reflect build busi
win translat meaning top-line growth dilig cost cut
effort mainstay boost target price
ep higher view
disrupt driver offer tangibl evid valu
proposit integr data offer integr continu track
ahead plan sinc im merger abil cover
sale pipelin proprietari integr data solut
current power clinic trial offer
signific budget time save custom fundament
outsourc demand remain robust evid biotech fund support
heighten clinic trial complex oner reimburs dynam
like fuel demand iqv value-ad servic forese
futur new technolog offer oce ai-autom trial plan
well discoveri level offer part next wave growth
meanwhil virtual trial concept earli day six on-going
forefront effort ahead competitor
valuat ep trade premium cro peer
histor average respect view
warrant inher advantag abil leverag unmatch
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
iqvia inc world largest contract research organ
cro lead healthcar inform technolog servic
price jun rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky scenario support bull
sotp scenario assum cost synergi im merger
exceed expect substanti cross sell cro
commerci servic exist new client greater new project
award due broader diversifi servic offer
pronounc strength spend fundament outsourc
grey sky scenario support bear
sotp scenario assum cost synergi take longer
expect captur integration-rel miscu includ
disrupt servic client capit deploy misstep
weaken demand outsourc relev
manag unveil updat medium-term three-year guidanc call
build momentum across technolog ta incl bp
research rd incl bp pass bp also call
ebitda growth vs provid investor day help
continu cost save increment million help support double-digit
ep growth medium term also updat net leverag target
exit vs may also appeas investor capit
deploy expect annual in-lin prior expect
capital-expenditure revenu vs revenu provid guid
net/net walk away investor day increment posit acceler
revenu growth continu prudent cost manag drive ebitda growth ahead
top-line
capital-expenditure defer softwar revenu
capital-expenditure defer softwar revenu
first allud futur cost save initi cs healthcar confer
novemb part vision initi investor day manag
detail target addit million cost save exit driven
greater effici process redesign artifici intellig machin learn
ai/ml procur oper off-set headwind includ
annual wage inflat deploy technolog platform contribut
research develop solut revenu
iqv research develop solut rd busi oper within total
address market billion grow mid-to-high singl digit
annual target cro top-line compound-annual-growth-rate ahead market includ
bp headwind pass-through bp tailwind growth
stem continu drug develop pipelin expans greater
outsourc penetr cs estimate per year market share gain estim
iqv share outsourc clinic develop lead
fragment yet consolid industri view above-market organ growth
sustain longer term leverag unmatch global proprietari
databas drive acceler new busi win billion merger date leverag
integr platform core-pow clinic develop contribut faster
site identif faster phase psychiatri trial exampl expedit site
start-up time quicker patient enrol specif expect util
biomark prescreen patient pool driver futur clinic trial product
rate unmatch cro peer due end-to-end data capabl billion
healthcar records/year million data feed vs billion respect
remain construct iqv posit within drug develop landscap
oncolog complex therapeut area continu repres grow
share pipelin drive demand effici outsourc capabl instanc
new activ substanc approv first-in-class next-gen
biotherapeut account overal pipelin compound vs
furthermor emerg ebp compani continu
repres greater share total pipelin
increasingli critic custom segment iqv iqvia offer launch februari
target approach toward ebp also util iqv critic
capabl initi alreadi shown success among smaller biopharma
captur busi ebp compani new custom
charl martineau pm univers toronto award billion formerli refer
trial custom two-third ebp compani
technolog analyt solut revenu
technolog analyt solut ta target compound-annual-growth-rate includ
bp consist past practic buoy grow demand real-
world evid mid-teen growth technolog platform doubl digit growth
includ newer orchestr custom engag oce notabl
experienc earli success oce platform compani vs
januari implement technolog suit enabl work close
healthcar provid user live oce platform vs
may deploy countri signific runway
remain estim billion market opportun sale lead
robust pipelin opportun recent launch genom
enabl greater effici conduct genom research cultiv research
real-world evid environ industri leader
figur iqv unchalleng domin world evid
lead expert rwd sourc
lead expert rwd analyt
lead expert gener rwe
applic market brand
term number access patient record largest healthcar
research platform world drive acceler effici insight across
commerci pharma end market patient popul grow complex
dashboard dissect million global patient record almost instantan
within regulatori oper industri experienc ever-ris cost complex
regulatori mainten effort peak level turn launch rim smart
manag solut life scienc system purpose-built autom
regulatori process inform aim reduc time spent complianc
rim smart capabl suggest appropri action product base
charl martineau pm univers toronto compani mention price
